These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28800129)

  • 1. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.
    Brinkmann K; Grabow S; Hyland CD; Teh CE; Alexander WS; Herold MJ; Strasser A
    Cell Death Differ; 2017 Dec; 24(12):2032-2043. PubMed ID: 28800129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.
    Mukherjee N; Lu Y; Almeida A; Lambert K; Shiau CW; Su JC; Luo Y; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
    Oncotarget; 2017 Jul; 8(29):46801-46817. PubMed ID: 27086916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
    Zhang R; Li Y; Dong X; Peng L; Nie X
    Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
    Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
    BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCL-1 dependency of cisplatin-resistant cancer cells.
    Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
    Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
    Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
    Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
    Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
    Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
    Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo.
    Sun JG; Li H; Li X; Zeng X; Wu P; Fung KP; Liu FY
    Apoptosis; 2014 May; 19(5):871-82. PubMed ID: 24563182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation.
    Sun JG; Ruan F; Zeng XL; Xiang J; Li X; Wu P; Fung KP; Liu FY
    Apoptosis; 2016 Oct; 21(10):1144-57. PubMed ID: 27421828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1.
    Li Q; Zhan M; Chen W; Zhao B; Yang K; Yang J; Yi J; Huang Q; Mohan M; Hou Z; Wang J
    Oncotarget; 2016 Mar; 7(9):10271-82. PubMed ID: 26848531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.
    Hira SK; Mondal I; Bhattacharya D; Gupta KK; Manna PP
    Int J Biochem Cell Biol; 2015 Oct; 67():1-13. PubMed ID: 26255115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.
    Feng C; Yang F; Wang J
    Cancer Gene Ther; 2017 Aug; 24(8):342-347. PubMed ID: 28776569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics.
    Rubio-Patiño C; Bossowski JP; Villa E; Mondragón L; Zunino B; Proïcs E; Chiche J; Bost F; Verhoeyen E; Ricci JE
    Oncotarget; 2016 Nov; 7(45):73270-73279. PubMed ID: 27689327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells.
    He K; Chen D; Ruan H; Li X; Tong J; Xu X; Zhang L; Yu J
    Oncotarget; 2016 Jul; 7(30):47699-47710. PubMed ID: 27351224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.